Edition:
United Kingdom

People: Aytu BioScience Inc (AYTU.OQ)

AYTU.OQ on NASDAQ Stock Exchange Capital Market

1.38USD
9:00pm BST
Change (% chg)

$-0.03 (-2.13%)
Prev Close
$1.41
Open
$1.40
Day's High
$1.40
Day's Low
$1.38
Volume
9,151
Avg. Vol
50,703
52-wk High
$4.80
52-wk Low
$0.69

Disbrow, Jarrett 

Mr. Jarrett T. (Josh) Disbrow is Chief Operating Officer of the Company. Jarrett Disbrow has been employed by us since April 16, 2015. Prior to the closing of the Merger, Mr. Disbrow was the Chief Executive Officer of Vyrix Pharmaceuticals from November 2013. Mr. Disbrow joined Vyrix from Eurus Pharma LLC, or Eurus Pharma, where he held the position of general manager from 2011 to 2013. Prior to joining Eurus Pharma, Mr. Disbrow was the founder, president and chief executive officer of Arbor Pharmaceuticals, Inc., or Arbor Pharmaceuticals from 2006 to 2010. Following Arbor Pharmaceuticals’ acquisition in 2010, Mr. Disbrow remained with the company as vice president of commercial development. Prior to founding Arbor Pharmaceuticals in 2006, he was head of marketing for Accentia Biopharmaceuticals, Inc. from 2002 to 2006. Mr. Disbrow began his career with GlaxoWellcome, Inc. (now GlaxoSmithKline plc) from 1997 to 2001, where he held positions of increasing responsibility in sales and later marketing. Mr. Disbrow received a BS in business management from North Carolina State University in Raleigh, NC. Mr. Disbrow served on our Board of Directors from April 2015 to July 2016.

Basic Compensation

Total Annual Compensation, USD 250,000
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 722,000
Fiscal Year Total, USD 972,000

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --